



Targeting  
New avenues and challenges  
SYMPOSIUM



2023

13<sup>th</sup> - 15<sup>th</sup> September

Targeting RAS

New challenges and avenues

SYMPOSIUM

[targetingras.com](http://targetingras.com)

**13**  
September

# Wednesday

8:00-9:00h	Registration
8:45-9:00h	Opening presentation / welcome speech (Eugenio Santos)

## Session 1: RAS driven mechanisms during tumour initiation & progression

Chairperson: Eugenio Santos

09:00h	Shiva Malek - Challenges and opportunities in treating KRAS mutant tumors
09:30h	Christopher Counter - Ras mutation tropism
10:00h	Dafna Bar-Sagi - Disruption of Immune Homeostasis Circuits in Mutant KRas Tumors
10:30h	Short talk selected from abstracts - Olesja Popow "Dissecting The Tissue-Specific Oncogenic Activity Of K-RasG12D"
10:45-11:15h	Coffee break

## Session 2: RAS & tumour microenvironment

Chairperson: Esther Castellano

11:15h	Julian Downward - Developing rational approaches to targeting RAS in combination with immune regulators
11:45h	David Tuveson - KRAS dependencies in Pancreatic Cancer
12:15h	Kairbaan Hodivala-Dilke - Enhancing immunotherapy in Kras driven lung cancer
12:45h	Short talk selected from abstracts - Alejandro Rosell "RAS-PI3K signaling: a master regulator of CAF phenotype to promote lung tumor progression"
13:00-14:30h	Lunch & poster session

## Session 3: RAS membrane dynamics & structural insights

Chairperson: David Santamaría

14:30h	Ruth Nussinov - How can same-gene mutations promote both cancer and developmental disorders?
15:00h	Chiara Ambrogio - Biological relevance of KRAS complexes interaction at the cell membrane
15:30h	Daniel Abankwa - Drug combinations with novel PDE6D inhibitors release differentiation block of oncogenic KRAS
16:00h	Short talk selected from abstracts - Milla Kurki "Exploring mutation-specific differences of KRAS: conformational dynamics and implications for effector-protein preferences"
16:15-16:45h	Coffee break

## Session 4: RAS isoforms and superfamily

Chairperson: Piero Crespo

16:45h	Ian Prior - Ras variant abundance and biology
17:15h	Udai Banerji - Proteomic profiling of KRAS signaling; Context, CAFs and Combinations
17:45h	Xosé Bustelo - "Out of the box" of RAS superfamily GTPases in cancer
18:15h	Short talk selected from abstracts I - Greg G Jones "Targeting the RAS Pathway through a First-in-Class DOCK5 Degradar"
18:30-18:45h	Short talk selected from abstracts II - Fernando Calvo Baltanas "Single and dual SOS1/SOS2 inhibition: evaluation of therapeutic effects and toxicity"
18:45h	End of day 1



14  
September

Thursday

### Session 5: Novel therapeutic approaches

Chairperson: Mathias Drosten

09:00h	Rene Bernards - New ideas to target RAS
09:30h	Mariano Barbacid - Targeting KRAS signalling
10:00h	Silve Vicent - Drug repurposing strategies for the treatment of mutant KRAS cancers
10:30h	Owen Samson - Understanding the role of endogenous and mutated KRAS in homeostasis and transformation of the colon
11:00h	Short talk selected from abstracts - Monica Musteanu "Avutometinib and FAK inhibitor concomitant treatment enhances antitumor efficacy of sotorasib in mice harboring KRASG12C;p53 mutant lung adenocarcinomas"
11:15-11:45h	Coffee break

### Session 6: Novel therapeutic approaches (Clinical perspective)

Chairperson: Pilar Garrido

11:45h	Kevan Shokat - Strategies for Drugging Undruggable Targets in Oncology With New Covalent Warheads
12:15h	Ernest Nadal - Current and future challenges in the clinical development of KRAS G12C inhibitors in non-small cell lung cancer
12:45h	Luis Paz Ares (Hospital Universitario 12 de Octubre, Madrid, Spain)
13:15h	Colin Lindsay - Applied biobanking to validate clinical vulnerabilities in RAS lung cancer variants
13:45h	Short talk selected from abstracts - Katrin J. Frank "Combination of the novel SHP2 inhibitor RMC-4550 and the novel ERK inhibitor LY3214996 for the treatment of KRAS mutant pancreatic cancer"
14:00-15:15h	Lunch & poster session

### Session 7: Novel therapeutic approaches (Pharmaceutical perspective)

Chairperson: Julian Downward

15:15h	Mathew Holderfield - Using Tri-Complex RAS(ON) Inhibitors to Target RAS
15:45h	James Christensen - Progress on selective targeting of KRAS mutant alleles and emerging clinical implications
16:15h	Pedro Beltrán - Targeting RAS-Driven PI3K $\alpha$ Activation in Human Tumors
16:45h	Barbara Nicke - Targeting KRAS via SOS1: Parallel Fragment Screening and HTS Approach
17:15h	Rati Verma - A clinical update on AMGEN's KRAS G12C-selective inhibitor Sotorasib and pre-clinical studies on a novel multi-KRAS inhibitor
17:45h	Short talk selected from abstracts - Barbara Mair "Assessment of KRAS mutant allele binding by covalent and non-covalent inhibitors through a cellular Switch-I/II and Switch-II pocket target engagement assay"
18:00-18:30h	Coffee break

### Session 8: Treatments & combinations to come (Round Table)

Chairperson: René Bernards

18:30-19:15h	Participants from pharma, clinic and academia (TBD)
19:30h	End of day 2
20:30h	Meeting dinner - Palacio de Figueroa - Calle Zamora, 15, 37002, Salamanca.

**15**  
September

Friday

## Session 9: RAS systems biology & novel signalling features (I)

Chairperson: Silve Vicent

- 09:00h Yibing Shan - A perfect storm—formation of Ras-Raf signalosome and its implications
- 09:30h Piero Crespo - Three Rs: RNA Regulates RAS-ERK signals
- 10:00h Pablo Rodríguez-Viciana - The SHOC2/MRAS/PP1 complex as a therapeutic target for RAS-driven cancers
- 10:30h Short talk selected from abstracts - Mukund Sharma "Convergence of RAS and PP2A activity on the phosphoregulation of chromatin repressor complexes"
- 10:45-11:15h Coffee break

## Session 10: RAS systems biology & novel signalling features (II)

Chairperson: Mariano Barbacid

- 11:15h Walter Kolch - Back to the future: the role of RAF kinases in RAS signaling and transformation
- 11:45h Channing Der - Targeting the KRAS-ERK-MYC signaling network for the treatment of KRAS-mutant pancreatic cancer
- 12:15h Christina Kiel - Ras-effector networks in (patho) physiological contexts
- 12:45h Short talk selected from abstracts - Patricia Santofimia Castaño "Targeting NUPR1-dependet Stress Granules Formation as an Efficient Strategy to Induce Synthetic Lethality In KrasG12D-Dependent Tumors"

## Session 11: Closing Lecture

- 13:00h Frank McCormick - The End of KRAS cancers?
- 13:45h End of meeting